Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Sutro Biopharma has disclosed Cash from Investing Activities across 9 years of filings, most recently posting $18.7 million for Q4 2025.

• Cash from Investing Activities for Q4 2025 came in at $18.7 million, down 78.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $45.0 million (down 79.4% YoY), and the FY2025 annual result was $45.0 million, down 79.4% from the prior year.
• Cash from Investing Activities came in at $18.7 million for Q4 2025 at Sutro Biopharma, down from $40.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $147.3 million in Q3 2024 to a low of -$121.7 million in Q1 2021.
• The 5-year median for Cash from Investing Activities is $12.3 million (2021), against an average of $6.4 million.
• Peak annual rise in Cash from Investing Activities reached 715.44% in 2022, while the deepest fall reached 3380.69% in 2022.
• Sutro Biopharma's Cash from Investing Activities stood at $20.8 million in 2021, then slumped by 282.29% to -$37.9 million in 2022, then surged by 37.93% to -$23.5 million in 2023, then surged by 472.08% to $87.5 million in 2024, then slumped by 78.62% to $18.7 million in 2025.
• The last three Cash from Investing Activities figures came in at $18.7 million (Q4 2025), $40.0 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.